LOXO-292 Demonstrates Promising Anti-Tumour Activity in RET-Altered Thyroid Cancer
The results from LIBRETTO-001 trial
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1631 results
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic Colorectal Cancer
TRIUMPH and MOUNTAINEER demonstrate promising clinical benefit for dual HER2 blockade in patients with HER2-amplified metastatic CRC; however, HERACLES-B did not meet the primary endpoint
First-Line Pembrolizumab Versus Chemotherapy in Patients with Advanced G/GEJ Cancer Demonstrates Similar Survival and HRQoL
A subset of patients with MSI-H tumours demonstrated superior benefit from pembrolizumab, both in combination with chemotherapy or as monotherapy
Molecular Classification Is Prognostic of Adjuvant Treatment Benefit in Patients with High-Risk Endometrial Cancer
Differences in patient outcome were observed in four molecular subgroups after adjuvant chemotherapy plus radiotherapy or radiotherapy
Gut Microbiota May Support an Immune Tolerant Profile That Affects Ipilimumab Activity
Gut microbial metabolites may alter the activity of immune blockade agents
Incorporating Veliparib into Chemotherapy and Continuing with Veliparib Maintenance Significantly Improved PFS in Newly Diagnosed High-Grade Serous Ovarian Cancer
The veliparib consisting regimen improved progression-free survival in the overall patient population and among women with BRCA mutation or HRD as compared to chemotherapy
Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial: Adding Olaparib to Bevacizumab Maintenance Demonstrates Substantial Clinical Benefit in Newly Diagnosed Advanced Ovarian Cancer
Progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy overall and across prespecified subgroups
Niraparib Prolongs PFS in Patients with Newly Diagnosed Advanced Ovarian Cancer
Niraparib administered after platinum-based chemotherapy improved progression-free survival in patients with ovarian cancer regardless of BRCA status
The Use of Complementary Medicines is Relatively High Among Patients in Phase III Cancer Trials
Complementary medicines are mostly used by younger patients with better performance status and fewer sites of metastasis
ctDNA From Patients with Colon Cancer Is Indicative of Outcome Following 3 Versus 6 Months of Oxaliplatin-Based Adjuvant Treatment
Circulating tumour DNA prior to adjuvant chemotherapy is a marker for disease-free survival in patients with stage III colon cancer
The EPIPHANY Index Assesses Risk of Short-Term Serious Complications in Patients with Cancer and Pulmonary Embolism
The EPIPHANY index was validated in a prospective PERSEO study
Nivolumab Combined with Ipilimumab or Alone Outperforms Ipilimumab at 5 Years in Advanced Melanoma
Long-term data from the CheckMate 067 study